A groundbreaking discovery in cancer research is shaking up the field, and it's all thanks to DNA barcoding. Imagine being able to track cancer cells like items in a store, but with profound implications for patient care! Australian researchers have revealed that DNA barcoding can be a game-changer in understanding and treating breast cancer.
Here's the deal: Tumors are complex, containing various cancer cells with different levels of aggression and treatment responses. The challenge lies in figuring out how solid and liquid biopsies, taken from tumors and blood respectively, can capture this diversity. And this is where DNA barcoding comes in.
This innovative technique involves using lentiviruses to attach unique DNA tags to individual cancer cells, much like barcodes on products. These tags can then be tracked and identified in tumor cells and matched with biopsy samples. Researchers from the Olivia Newton-John Cancer Research Institute, WEHI, and Peter MacCallum Cancer Centre optimized this method and made a fascinating find: Even when tumors appear similar, they can release varying amounts of DNA into the bloodstream.
In a groundbreaking achievement, the team successfully detected these DNA barcodes in blood and plasma samples, a world-first. But here's where it gets controversial: They found that DNA tag detectability differs across models, with some highly metastatic tumors showing low recovery. This suggests that DNA shedding is model-specific, potentially leading to false-negative liquid biopsy results.
Dr. Antonin Serrano, a key researcher, explains, "DNA barcoding allowed us to examine entire tumors, solid biopsies, and liquid biopsies, quantifying tumor heterogeneity in biopsies. We discovered that DNA shedding in the bloodstream varies widely, influenced by necrosis, tumor burden, and preclinical models." And this is the part most people miss: The center of primary tumors had significantly higher barcode diversity than the periphery, which may impact solid biopsy interpretations.
Prof. Delphine Merino, a senior author, adds, "Our findings indicate that both liquid and solid biopsies generally represent tumor composition, but with variations between tumors. Combining both approaches may offer a more precise disease picture." Prof. Sarah-Jane Dawson, a co-senior author and breast cancer clinician, highlights the importance of this research for liquid biopsies, a non-invasive disease monitoring method. She believes it will help explain why some tumors shed more DNA and improve their clinical use.
With over 20,000 new breast cancer cases in Australia in 2025 and an estimated 3,353 deaths, this research is a significant step forward. Dr. Tom Weber and Prof. Shalin Naik, co-authors of the study, have contributed to this exciting advancement in cancer research.
